A citation-based method for searching scientific literature

Annemarie B van der Aart-van der Beek, Rudolf A de Boer, Hiddo J L Heerspink. Nat Rev Nephrol 2022
Times Cited: 4







List of co-cited articles
10 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, João P Ferreira, Edimar Bocchi, Michael Böhm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela,[...]. N Engl J Med 2021
449
75

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
947
75

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
202
50

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
321
50


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Hiddo J L Heerspink, David Cherney, Douwe Postmus, Bergur V Stefánsson, Glenn M Chertow, Jamie P Dwyer, Tom Greene, Mikhail Kosiborod, Anna Maria Langkilde, John J V McMurray,[...]. Kidney Int 2022
9
50

Impact of Sacubitril-Valsartan on Markers of Glomerular Function.
Gregorio Tersalvi, Jeroen Dauw, Pieter Martens, Wilfried Mullens. Curr Heart Fail Rep 2020
9
25

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
Kevin Damman, Mauro Gori, Brian Claggett, Pardeep S Jhund, Michele Senni, Martin P Lefkowitz, Margaret F Prescott, Victor C Shi, Jean L Rouleau, Karl Swedberg,[...]. JACC Heart Fail 2018
150
25

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
Adriaan A Voors, Mauro Gori, Licette C Y Liu, Brian Claggett, Michael R Zile, Burkert Pieske, John J V McMurray, Milton Packer, Victor Shi, Martin P Lefkowitz,[...]. Eur J Heart Fail 2015
125
25

Atrial natriuretic peptide regulation of endothelial permeability is mediated by cGMP.
C E Lofton, W H Newman, M G Currie. Biochem Biophys Res Commun 1990
59
25

Diabetes and Trajectories of Estimated Glomerular Filtration Rate: A Prospective Cohort Analysis of the Atherosclerosis Risk in Communities Study.
Bethany Warren, Casey M Rebholz, Yingying Sang, Alexandra K Lee, Josef Coresh, Elizabeth Selvin, Morgan E Grams. Diabetes Care 2018
25
25

Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.
Iris E Beldhuis, Carolyn S P Lam, Jeffrey M Testani, Adriaan A Voors, Harriette G C Van Spall, Jozine M Ter Maaten, Kevin Damman. Circulation 2022
2
50


Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.
Jozine M Ter Maaten, Kevin Damman, Marianne C Verhaar, Walter J Paulus, Dirk J Duncker, Caroline Cheng, Loek van Heerebeek, Hans L Hillege, Carolyn S P Lam, Gerjan Navis,[...]. Eur J Heart Fail 2016
177
25

LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.
Wanghui Jing, Nosratola D Vaziri, Ane Nunes, Yasunori Suematsu, Ted Farzaneh, Mahyar Khazaeli, Hamid Moradi. Am J Transl Res 2017
55
25

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.
Alexander Peikert, Muthiah Vaduganathan, Finnian Mc Causland, Brian L Claggett, Safia Chatur, Milton Packer, Marc A Pfeffer, Faiez Zannad, Martin P Lefkowitz, Burkert Pieske,[...]. Eur J Heart Fail 2022
3
33

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction.
Robert J Mentz, Jacob P Kelly, Thomas G von Lueder, Adriaan A Voors, Carolyn S P Lam, Martin R Cowie, Keld Kjeldsen, Ewa A Jankowska, Dan Atar, Javed Butler,[...]. J Am Coll Cardiol 2014
312
25

The renal and cardiovascular effects of natriuretic peptides.
Philip Ching Yat Wong, Jun Guo, Aidong Zhang. Adv Physiol Educ 2017
42
25

Pathogenetic mechanisms of diabetic nephropathy.
Francesco P Schena, Loreto Gesualdo. J Am Soc Nephrol 2005
378
25

The outcomes of continuous ambulatory and automated peritoneal dialysis are similar.
Rajnish Mehrotra, Yi-Wen Chiu, Kamyar Kalantar-Zadeh, Edward Vonesh. Kidney Int 2009
79
25

Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.
Ramón Paniagua, Dante Amato, Edward Vonesh, Ricardo Correa-Rotter, Alfonso Ramos, John Moran, Salim Mujais. J Am Soc Nephrol 2002
704
25

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.
Nikole J Byrne, Nirmal Parajuli, Jody L Levasseur, Jamie Boisvenue, Donna L Beker, Grant Masson, Paul W M Fedak, Subodh Verma, Jason R B Dyck. JACC Basic Transl Sci 2017
94
25

Causes of Death in End-Stage Kidney Disease: Comparison between the United States Renal Data System and a Large Integrated Health Care System.
Simran K Bhandari, Hui Zhou, Sally F Shaw, Jiaxiao Shi, Natasha S Tilluckdharry, Connie M Rhee, Steven J Jacobsen, John J Sim. Am J Nephrol 2022
1
100

Renal Anti-Fibrotic Effect of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension.
Giovanna Castoldi, Raffaella Carletti, Silvia Ippolito, Massimiliano Colzani, Francesca Barzaghi, Andrea Stella, Gianpaolo Zerbini, Gianluca Perseghin, Cira R T di Gioia. Am J Nephrol 2020
16
25

SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.
Fateen Ata, Zohaib Yousaf, Adeel Ahmad Khan, Almurtada Razok, Jaweria Akram, Elrazi Awadelkarim Hamid Ali, Ahmed Abdalhadi, Diaeldin Abdelgalil Ibrahim, Dabia Hamad S H Al Mohanadi, Mohammed I Danjuma. Sci Rep 2021
10
25


Peritoneal Expression of SGLT-2, GLUT1, and GLUT3 in Peritoneal Dialysis Patients.
Severin Schricker, Tina Oberacker, Peter Fritz, Markus Ketteler, Mark Dominik Alscher, Moritz Schanz. Kidney Blood Press Res 2022
3
33

A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Yifan Zhang, Daisuke Nakano, Yu Guan, Hirofumi Hitomi, Akiyoshi Uemura, Tsutomu Masaki, Hideki Kobara, Takeshi Sugaya, Akira Nishiyama. Kidney Int 2018
72
25

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
Emily Brown, Hiddo J L Heerspink, Daniel J Cuthbertson, John P H Wilding. Lancet 2021
41
25

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Andrew S Levey, Ron T Gansevoort, Josef Coresh, Lesley A Inker, Hiddo L Heerspink, Morgan E Grams, Tom Greene, Hocine Tighiouart, Kunihiro Matsushita, Shoshana H Ballew,[...]. Am J Kidney Dis 2020
160
25

Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports.
Caroline Bartolo, Victoria Hall, N Deborah Friedman, Chloe Lanyon, Andrew Fuller, C Orla Morrissey, Eugene Athan. BMC Infect Dis 2021
2
50

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes.
Oriol Iborra-Egea, Evelyn Santiago-Vacas, Salva R Yurista, Josep Lupón, Milton Packer, Stephane Heymans, Faiez Zannad, Javed Butler, Domingo Pascual-Figal, Antonio Lax,[...]. JACC Basic Transl Sci 2019
40
25

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
254
25

Serum Hepcidin-25 and Risk of Mortality in Patients on Peritoneal Dialysis.
Zhong Zhong, Dan Luo, Ning Luo, Bin Li, Dongying Fu, Li Fan, Zhijian Li, Wei Chen, Haiping Mao. Front Med (Lausanne) 2021
1
100

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
Gert J Mayer, Christoph Wanner, Matthew R Weir, Silvio E Inzucchi, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z I Cherney. Kidney Int 2019
58
25

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, George Bakris, Christopher P Cannon, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Adeera Levin,[...]. Kidney Int 2021
32
25

SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis.
Giedre Martus, Karin Bergling, Javier de Arteaga, Carl M Öberg. Perit Dial Int 2021
5
25

A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease.
Lucia Del Vecchio, Angelo Beretta, Carlo Jovane, Silvia Peiti, Simonetta Genovesi. Drugs 2021
9
25

COVID-19 pandemic era: is it time to promote home dialysis and peritoneal dialysis?
Mario Cozzolino, Ferruccio Conte, Fulvia Zappulo, Paola Ciceri, Andrea Galassi, Irene Capelli, Giacomo Magnoni, Gaetano La Manna. Clin Kidney J 2021
6
25

Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis.
Cheuk-Chun Szeto, Bonnie Ching-Ha Kwan, Kai-Ming Chow, Sebastian Chung, Vincent Yu, Phyllis Mei-Shan Cheng, Chi-Bon Leung, Man-Ching Law, Philip Kam-Tao Li. Perit Dial Int 2015
44
25

Preservation of residual kidney function in hemodialysis patients: reviving an old concept.
Anna T Mathew, Steven Fishbane, Yoshitsugu Obi, Kamyar Kalantar-Zadeh. Kidney Int 2016
90
25

Rate of Decline of Residual Kidney Function Before and After the Start of Peritoneal Dialysis.
Lian He, Xihui Liu, Zi Li, Zita Abreu, Tushar Malavade, Charmaine E Lok, Joanne M Bargman. Perit Dial Int 2016
16
25

Rationale and Strategies for Preserving Residual Kidney Function in Dialysis Patients.
Tian Li, Christopher S Wilcox, Michael S Lipkowitz, Judit Gordon-Cappitelli, Serban Dragoi. Am J Nephrol 2019
14
25

SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate.
Michael S Balzer, Song Rong, Johannes Nordlohne, Jan D Zemtsovski, Sonja Schmidt, Britta Stapel, Maria Bartosova, Sibylle von Vietinghoff, Hermann Haller, Claus P Schmitt,[...]. Biomolecules 2020
6
25

Timing, causes, predictors and prognosis of switching from peritoneal dialysis to hemodialysis: a prospective study.
Bernard G Jaar, Laura C Plantinga, Deidra C Crews, Nancy E Fink, Nasser Hebah, Josef Coresh, Alan S Kliger, Neil R Powe. BMC Nephrol 2009
86
25

Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction.
Rio P Juni, Rushd Al-Shama, Diederik W D Kuster, Jolanda van der Velden, Henrike M Hamer, Marc G Vervloet, Etto C Eringa, Pieter Koolwijk, Victor W M van Hinsbergh. Kidney Int 2021
16
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.